Literature DB >> 15970480

Uncoupling protein-2 and non-alcoholic fatty liver disease.

György Baffy1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) has become the most common form of hepatic disorders in the developed world. NAFLD is part of the metabolic syndrome with insulin resistance as a primary underlying derangement. The natural history of NAFLD may extend from simple steatosis over steatohepatitis into cirrhosis and hepatocellular carcinoma. Among numerous factors shaping these transitions, uncoupling protein-2 (UCP2) may theoretically contribute to every stage of this disease. UCP2 is a recently identified fatty acid-responsive mitochondrial inner membrane carrier protein showing wide tissue distribution with a substantially increased presence in fatty liver. The biological functions of UCP2 are not fully elucidated and the greater part of our current knowledge has been obtained from animal experiments. These data suggest a role for UCP2 in lipid metabolism, mitochondrial bioenergetics, oxidative stress, apoptosis, and even carcinogenesis. Available evidence is reviewed and new concepts are considered to appraise the potential role of UCP2 in the pathogenesis of NAFLD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15970480     DOI: 10.2741/1683

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  24 in total

1.  Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury.

Authors:  Mingyan Zhou; Aimin Xu; Paul K H Tam; Karen S L Lam; Lawrence Chan; Ruby L C Hoo; Jing Liu; Kim H M Chow; Yu Wang
Journal:  Hepatology       Date:  2008-10       Impact factor: 17.425

2.  Synergistic activation of mitochondrial metabolism and the glutathione redox couple protects HepG2 hepatocarcinoma cells from palmitoylcarnitine-induced stress.

Authors:  Patrick C Turnbull; Ali C Dehghani; Christopher F Theriau; Michael K Connor; Christopher G R Perry
Journal:  Am J Physiol Cell Physiol       Date:  2019-10-16       Impact factor: 4.249

3.  TRPV1 activation prevents nonalcoholic fatty liver through UCP2 upregulation in mice.

Authors:  Li Li; Jing Chen; Yinxing Ni; Xiaoli Feng; Zhigang Zhao; Peijian Wang; Jing Sun; Hao Yu; Zhencheng Yan; Daoyan Liu; Bernd Nilius; Zhiming Zhu
Journal:  Pflugers Arch       Date:  2012-03-07       Impact factor: 3.657

4.  Effect of berberine on expressions of uncoupling protein-2 mRNA and protein in hepatic tissue of non-alcoholic fatty liver disease in rats.

Authors:  Qin-He Yang; Si-Ping Hu; Yu-Pei Zhang; Wei-Ning Xie; Na Li; Gui-Yuan Ji; Na-Li Qiao; Xiu-Feng Lin; Tong-Yan Chen; Hai-Tao Liu
Journal:  Chin J Integr Med       Date:  2011-02-27       Impact factor: 1.978

5.  Proteomic analysis of liver mitochondria from rats with nonalcoholic steatohepatitis.

Authors:  Lin Li; De-Zhao Lu; You-Ming Li; Xue-Qun Zhang; Xin-Xin Zhou; Xi Jin
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

Review 6.  Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

Authors:  György Baffy
Journal:  J Hepatol       Date:  2009-03-31       Impact factor: 25.083

Review 7.  Allostasis in nonalcoholic fatty liver disease: implications for risk assessment.

Authors:  György Baffy
Journal:  Dig Dis Sci       Date:  2012-08-11       Impact factor: 3.199

8.  Cranberry extract attenuates hepatic inflammation in high-fat-fed obese mice.

Authors:  Shannon L Glisan; Caroline Ryan; Andrew P Neilson; Joshua D Lambert
Journal:  J Nutr Biochem       Date:  2016-08-04       Impact factor: 6.048

9.  Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis.

Authors:  Brendan N Reid; Gene P Ables; Oleg A Otlivanchik; Gabriele Schoiswohl; Rudolf Zechner; William S Blaner; Ira J Goldberg; Robert F Schwabe; Streamson C Chua; Li-Shin Huang
Journal:  J Biol Chem       Date:  2008-03-12       Impact factor: 5.157

Review 10.  Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease.

Authors:  Peter R Baker; Jacob E Friedman
Journal:  J Clin Invest       Date:  2018-08-31       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.